Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Zhejiang Jiuzhou Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zhejiang Jiuzhou Pharmaceutical Co is: High Risk: Good fundamentals, beware of shrinking business.

Competitive Comparison of Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment falls into.

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zhejiang Jiuzhou Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zhejiang Jiuzhou Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Jiuzhou Pharmaceutical Co Ltd (SHSE:603456) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

99 Waisha Road, Jiaojiang District, Taizhou, Zhejiang, CHN, 318000

Website

http://www.jiuzhoupharma.com

Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.

Executives

Sha Yu Jie	Directors, senior managers
Mei Yi Jiang	Director
Li Yuan Qiang	senior management
Yang Nong Gang	senior management
	Directors, senior managers
Huang Min Xia	senior management
Wang Bin	Directors, senior managers
Dai Yun You	senior management
Jiang Zu Lin	Directors, senior managers
Guo Zhen Rong	senior management
Chen Zhi Hong	Directors, senior managers
Xu Jia Jun	Supervisors
Hua Li Rong	Director
Lin Hui Lu	senior management
Zhu Guo Liang	Supervisors

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Headlines

No Headlines